Resolution of the Advisory board “Modern treatment approaches for advanced Renal cell carcinoma”
https://doi.org/10.18027/2224-5057-2017-3-89-92
Abstract
The article presents the results of the meeting of the Advisory board “Modern treatment approaches for advanced renal cell carcinoma”, held on Apr 24, 2017, with the aim to discuss current approaches to inoperable, locally advanced and advanced renal cell carcinoma. To discuss the Russian experience with lenvatinib in the routine clinical practice and get the experts’ opinion on the perspectives directions of lenvatinib study in renal cell carcinoma landscape.
About the Authors
B. Y. Alexeev
FSBI National Medical Research Radiological Center of the Ministry of Health of the Russian Federation;
N.A. Lopatkin Research Institute of Urology and Interventional Radiology – brunch of FSBI National Medical Research Radiological Center
Russian Federation
PhD, Professor., Scientific Secretary of the Russian Cancer Society, Deputy General Director for Research, FSBI National Medical Research Radiological Center of the Ministry of Health of the Russian Federation; Deputy Director for Research, FSBI N.A. Lopatkin Research Institute of Urology and Interventional Radiology - brunch of FSBI NMRRC of the Ministry of Health of the Russian Federation
Russian Federation
PhD, Professor., Scientific Secretary of the Russian Cancer Society, Deputy General Director for Research, FSBI National Medical Research Radiological Center of the Ministry of Health of the Russian Federation; Deputy Director for Research, FSBI N.A. Lopatkin Research Institute of Urology and Interventional Radiology - brunch of FSBI NMRRC of the Ministry of Health of the Russian Federation
A. V. Alyasova
FSBI Volga District Medical Centre under FMBA
Russian Federation
PhD, Professor, Department of Oncology FPKV
Russian Federation
PhD, Professor, Department of Oncology FPKV
M. I. Volkova
FSBI N. N. Blokhin Russian Cancer Research Center
Russian Federation
PhD, Senior Researcher, Department of Oncourology
Russian Federation
PhD, Senior Researcher, Department of Oncourology
S. L. Gutorov
FSBI N. N. Blokhin Russian Cancer Research Center
Russian Federation
PhD, Leading Researcher, Department of Chemotherapy and Combined Treatment of Malignant Tumors
Russian Federation
PhD, Leading Researcher, Department of Chemotherapy and Combined Treatment of Malignant Tumors
V. B. Matveev
FSBI N. N. Blokhin Russian Cancer Research Center
Russian Federation
PhD, Professor, President of the Russian Society of Oncourologists, Corresponding Member of Russian Academy of Science, Head of the Department of Oncourology
Russian Federation
PhD, Professor, President of the Russian Society of Oncourologists, Corresponding Member of Russian Academy of Science, Head of the Department of Oncourology
A. M. Popov
FSBI Central Clinical Hospital of the Presidential Administration of the Russian Federation
Russian Federation
PhD, Head of the Department of Urology, FSBI Central Clinical Hospital of the Presidential Administration of the Russian Federation, RUSSCO member
Russian Federation
PhD, Head of the Department of Urology, FSBI Central Clinical Hospital of the Presidential Administration of the Russian Federation, RUSSCO member
I. G. Rusakov
Moscow City Oncology Hospital No. 57, Moscow Healthcare Department
Russian Federation
PhD, Professor., Vice-president of the Russian Society of Oncourologists, Deputy Chief Physician for Oncology Care
Russian Federation
PhD, Professor., Vice-president of the Russian Society of Oncourologists, Deputy Chief Physician for Oncology Care
G. Y. Kharkevich
FSBI N. N. Blokhin Russian Cancer Research Center
Russian Federation
PhD, Leading Researcher, Department of Tumor Biotherapy, FSBI N.N. Blokhin Russian Cancer Research Center member of the working group for development of practical recommendations RUSSCO
Russian Federation
PhD, Leading Researcher, Department of Tumor Biotherapy, FSBI N.N. Blokhin Russian Cancer Research Center member of the working group for development of practical recommendations RUSSCO
References
1. Motzer R. J., Escudier B., McDermott D. F. et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N. Engl. J. Med., 2015 Nov 5; Vol. 373 (19), pp. 1803–1813. DOI: 10.1056 / NEJMoa1510665. Epub 2015 Sep 25.
2. Choueiri T. K., Escudier B., Powles T. et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma, N. Engl. J. Med., 2015 Nov 5, Vol. 373 (19), pp. 1814–23. DOI: 10.1056 / NEJMoa1510016.
3. Motzer R. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial, Lancet Oncol., 2015, Vol. 16, pp.:1473–1482.
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Kidney Cancer version 2.2017 – October 31, 2016. Available at: https://www.nccn.org / professionals / physician_gls / pdf / kidney. pdf.
5. Клинические рекомендации по лечению рака паренхимы почки у взрослых, утверждены Российским обществом урологов, подготовлены совместно со специалистами Российского общества онкоурологов и Ассоциации онкологов России. Доступны на сайте Министерства Здравоохранения Российской Федерации. URL: http://cr.rosminzdrav.ru / schema. html?id=87# / text. [Klinicheskie rekomendatsii po lecheniyu raka parenkhimy pochki u vzroslykh, utverzhdeny Rossiyskim obshchestvom urologov, podgotovleny sovmestno so spetsialistami Rossiyskogo obshchestva onkourologov i Assotsiatsii onkologov Rossii. Available at: http://cr.rosminzdrav.ru / schema. html?id=87# / text (In Russ.)].
6. Инструкция по медицинскому применению препарата Афинитор® (эверолимус): РУ ЛП – 002288 от 28.10.2013. [Instructions for the medical use of the drug Afinitor® (everolimus): RU PL – 002288 dated 10.28.2013 (In Russ.)].
7. Инструкция по медицинскому применению препарата Инлита® (акситиниб): РУ ЛП-003983 от 29.11.2016. [Instructions for the medical use of the preparation of Inlita® (axitinib): RU LP-003983 dated 11.29.2016 (In Russ.)].
8. Инструкция по медицинскому применению препарата Опдиво® (ниволумаб): РУ ЛП – 004026 от 22.12.2016 [Instructions for the medical use of the drug Opdivo® (nivolumab): RU PL – 004026 dated 12.12.2016 (In Russ.)].
9. Инструкция по медицинскому применению препарата Ленвима® (ленватиниб): РУ ЛП – 003398 от 29.12.2015, с изменениями от 06.12.2016. [Instructions for the medical use of Lenvima® (lenvatinib): RU PL – 003398 dated 29.12.2015, as amended on 06.12.2016 (In Russ.)].
Review
For citations:
Alexeev B.Y., Alyasova A.V., Volkova M.I., Gutorov S.L., Matveev V.B., Popov A.M., Rusakov I.G., Kharkevich G.Y. Resolution of the Advisory board “Modern treatment approaches for advanced Renal cell carcinoma”. Malignant tumours. 2017;(3):89-92. (In Russ.) https://doi.org/10.18027/2224-5057-2017-3-89-92
Views:
742
Email this article 